{"DataElement":{"publicId":"2833924","version":"1","preferredName":"Hormone Therapy Discontinued Type","preferredDefinition":"the type of hormonal therapy that was discontinued.","longName":"HORMTX_DISCONTINU_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2433918","version":"1","preferredName":"Hormone Therapy Discontinued","preferredDefinition":"information related to the stopping of the administered hormone therapy to an individual.","longName":"HORMONALTX_DISCONT","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2433915","version":"1","preferredName":"Hormone Therapy","preferredDefinition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level. The treatment may include administration of hormones or hormone analogs to the patient, or decreasing the level of hormones in the body by using hormone antagonists, or hormone ablation therapy. The concept covers but not limited to: intermittent or permanent hormone suppression or ablation in treatment of hormone-dependent tumors, hormone replacement therapy of any kind, hormonal component of gender reassignment therapy, hormonal contraception, surgical and radiation castration.","longName":"C15445","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hormone Therapy","conceptCode":"C15445","definition":"Various treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDA8-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2433916","version":"1","preferredName":"Discontinued","preferredDefinition":"Discontinued; stopped permanently or temporarily.","longName":"C25484","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Discontinue","conceptCode":"C25484","definition":"To stop or end, permanently or temporarily.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDA9-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"06674CCB-CDAA-04A9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2833920","version":"1","preferredName":"Hormone Therapy Discontinued Type","preferredDefinition":"the type of hormonal therapy that was discontinued.","longName":"HORMTX_DISCONTINU_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"40","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"622F9D40-EE32-7E53-E040-BB89AD432BC4","beginDate":"2009-02-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-02-05","modifiedBy":"ONEDATA","dateModified":"2009-02-05","deletedIndicator":"No"},{"value":"Aromatase Inhibitor","valueDescription":"Aromatase inhibitor","ValueMeaning":{"publicId":"2571015","version":"1","preferredName":"Aromatase inhibitor","longName":"2571015","preferredDefinition":"An agent that blocks the function of the enzyme aromatase with antineoplastic activity.  Aromatase inhibitors belong to two classes: Type I steroidal drugs are androgen substrate analogues that bind competitively but irreversibly to the enzyme.  Type II nonsteroidal inhibitors fit into the substrate binding site and bind reversibly to the enzyme.  Present in many tissues, aromatases are heme-containing enzymes that catalyze the adrenal conversion of cholesterol to pregnenolone and the peripheral conversion (aromatization) of androgenic precursors to estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aromatase Inhibitor","conceptCode":"C1740","definition":"Any substance that inhibits aromatase, an enzyme responsible for the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Inhibition of aromatase results in the suppression of estrogen-regulated processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E274-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-07-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-07-07","modifiedBy":"ALAIS","dateModified":"2007-06-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"622F9D40-EE3C-7E53-E040-BB89AD432BC4","beginDate":"2009-02-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-02-05","modifiedBy":"ONEDATA","dateModified":"2009-02-05","deletedIndicator":"No"},{"value":"Tamoxifen","valueDescription":"TAMOXIFEN","ValueMeaning":{"publicId":"2561706","version":"1","preferredName":"TAMOXIFEN","longName":"2561706","preferredDefinition":"TAMOXIFEN","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE17-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"622F9D40-EE47-7E53-E040-BB89AD432BC4","beginDate":"2009-02-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-02-05","modifiedBy":"ONEDATA","dateModified":"2009-02-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008554","version":"1","preferredName":"Treatment/Off-treatment Reasons","preferredDefinition":"justification for or explanation of the administration or cessation of therapy.","longName":"TX_OTX_RSNS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2C9BE32-8BDB-649C-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"622F9D40-EE1E-7E53-E040-BB89AD432BC4","latestVersionIndicator":"Yes","beginDate":"2009-02-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-02-05","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Hormonal Agent When Hormonal","type":"Preferred Question Text","description":"Hormonal Agent When Hormonal Therapy was Permanently Discontinued","url":null,"context":"CTEP"}],"origin":"NSABP CRF:National Surgical Adjuvant Breast and Bowel Project Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"622FAAE3-8E82-A5BA-E040-BB89AD435E19","latestVersionIndicator":"Yes","beginDate":"2009-02-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2009-02-05","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}